Drug Approval | January 08, 2026
Rapid-acting ADHD treatment Azstarys now approved in China
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Subscribe To Our Newsletter & Stay Updated
